- Home
- BSRR vs PHAT Comparison
BSRR vs PHAT Comparison
Compare BSRR & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSRR | PHAT |
|---|---|---|
| Founded | 1977 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.2M | 590.6M |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BSRR | PHAT |
|---|---|---|
| Price | $40.33 | $7.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $43.00 | $20.09 |
| AVG Volume (30 Days) | 40.3K | ★ 1.2M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | 10.28 | ★ 42.72 |
| EPS | ★ 1.72 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $0.85 | $80.58 |
| Revenue Next Year | $3.64 | $56.62 |
| P/E Ratio | $23.02 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $26.62 | $6.52 |
| 52 Week High | $43.13 | $18.31 |
Technical Indicators
Market Signals| Indicator | BSRR | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 43.18 |
| Support Level | $38.98 | $6.72 |
| Resistance Level | $41.06 | $7.72 |
| Average True Range (ATR) | 0.98 | 0.40 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 89.52 | 42.50 |
Price Performance
Historical ComparisonAbout BSRR Sierra Bancorp
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. It offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.